Ofichem Acquired Kinentia Biosciences
The Dutch organization has reached a deal to purchase the New York-based drug developer.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Should the US government restrict the acquisition of domestic biotech firms by foreign corporations?
Dutch contract development firm Ofichem has signed a definitive agreement to acquire the New York-based organization Kinentia Biosciences. This strategic move marks a significant expansion of the group's operations into the United States.
Why it matters
The acquisition is intended to bridge the gap between Kinentia's early-stage drug development focus and Ofichem's established manufacturing capabilities in Europe. By integrating these assets, the group aims to create a comprehensive development and production footprint across two continents.
The deal involves an acquisition of a U.S.-based drug substance contract development and manufacturing organization. Financial terms of the agreement were not disclosed.
The players
Ofichem
Ofichem is a Dutch contract development and manufacturing organization that specializes in chemical services for the pharmaceutical industry.
Kinentia Biosciences
Kinentia Biosciences is a drug substance contract development and manufacturing organization based in Rensselaer, New York.
The details
Ofichem, a Dutch contract development and manufacturing organization, plans to utilize this merger to bolster its international reach. The transaction is currently pending regulatory review to ensure all closing conditions are satisfied.
Timeline
October 6, 2026: Ofichem and Kinentia Biosciences signed the definitive acquisition agreement.
Market Landscape
This move reflects a broader trend of international consolidation in the pharmaceutical supply chain as firms seek to integrate development and production. The transaction follows standard global industry patterns by remaining subject to approval by the Committee on Foreign Investment in the United States.
For the average client, this integration promises a more unified drug development process spanning both European and American facilities. The deal does not immediately alter retail pricing or consumer access to specific pharmaceutical products.
The takeaway
Strategic acquisitions like this allow global contract organizations to provide end-to-end services from initial drug development to final manufacturing. Clients in the pharmaceutical industry should watch for potential service expansion as these two entities align their workflows.
What happens next
The companies expect to complete the transaction following regulatory approval and the satisfaction of customary closing conditions.
Further reading
Learn more about the latest developments in the sector on the Healthcare page.
Source note: This article includes information reported by Thepharmaletter.
Live Poll
Should the US government restrict the acquisition of domestic biotech firms by foreign corporations?
